Cancer cells evolve, so does our science
Relentless and innovative thinking that keeps our science one step ahead, always!
Our Science
We are all in to make it possible
Coming Soon
Dr Swaroop Vakkalanka
Founder & MD, Incozen Therapeutics
Dr Srikant Viswanadha
Sr VP, Research
Dr Ajit Nair
Sr VP, Clinical Development
Mr Vatsa Natarajan
Sr VP, Development and Commercial Strategy
Publications
Pooled Safety Analysis and Efficacy of Tenalisib (RP6530), a PI3K δ/ γ Inhibitor in Patients with Relapsed/Refractory Lymphoid Malignancies
Read More +
Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study
Read More +
Addition of RP6530, a dual PI3Kδ/γ inhibitor, accentuates Romidepsin activity in NHL cells in vitro
Read More +
Safety and Anti-Tumour Activity of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor, in Relapsed/Refractory T-Cell Lymphoma: Updated Results from the Dose Expansion Cohort of an on-Going Phase I/Ib Study
Read More +
Antitumor activity of RP4010, a novel small-molecule inhibitor of the calcium release-activated calcium (CRAC) channel pathway
Read More +
Store-operated calcium signaling is an effective therapeutic target in Acute Myeloid Leukemia (AML)
Read More +Partner With Us
Our approach to partnering is simple and yet effective. We are looking to collaborate with partners having synergistic capabilities and programs. Our successful track record of partnerships with the likes of TG Therapeutics, Novartis etc., bear testimony to our win-win approach.
We have an affiliate entities & offices located across US, EU and India to facilitate our collaborative approach to a developing & commercializing a globally competitive pipeline.
Contact Us